This study will evaluate real world pattern of use of BOTOX® in actual clinical practice in patients with idiopathic overactive bladder (iOAB) with urinary incontinence whose symptoms have not been adequately managed by oral anticholinergic therapy.
Study Type
OBSERVATIONAL
Enrollment
515
botulinum toxin Type A administered in accordance with physician standard practice.
Percentage of Patients Who have Greatly Improved or Improved on the 4-Point Treatment Benefit Scale (TBS)
Time frame: Baseline, Week 12
Change From Baseline in Number of Urinary Incontinence Episodes
Time frame: Baseline, Week 12
Time to Re-Injection of BOTOX®
Time frame: 12 Months
Number of Nocturia Episodes
Time frame: 12 Months
Usage of Incontinence Support Products
Time frame: 12 Months
Percentage of Patients Who Have at Least a 50% Reduction in Urinary Incontinence and Urinary Urgency Incontinence
Time frame: Baseline, 12 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
David Brix
Bad Mergentheim, Germany
Urologie Turmschtraße
Berlin, Germany
Uwe-Carsten
Berlin, Germany
Albrecht Kastein
Berlin, Germany
ATURO
Berlin, Germany
MVZ Burgdorf
Burgdorf, Hanover, Germany
Ev.-Luth. Diakonissenanstalt Dresden
Dresden, Germany
Stefan Carl
Emmendingen, Germany
Zentrum für Urologie FFM
Frankfurt, Germany
Georg-August-Universität Göttingen
Göttingen, Germany
...and 44 more locations